Atopic Dermatitis

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.

Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.

Significant improvement in Worst Scratch and Itch NRS score, Skin Clearance, and Children’s Dermatology Life Quality Index (CDLQI).

Efficacy is shown through 3 years of disease control, impact on growth curve, and improvement in mental health.​

The Hidden Impact of CLCI in Dermatology

Dr Joseph Toh clears up common myths about Atopic Dermatitis and explains what every patient should know about managing the condition.